
==== Front
J Endocrinol Invest
J Endocrinol Invest
Journal of Endocrinological Investigation
0391-4097
1720-8386
Springer International Publishing Cham

38565814
2320
10.1007/s40618-024-02320-7
Original Article
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
http://orcid.org/0000-0002-8666-4849
Dei Cas A. alessandra.deicas@unipr.it

12
Micheli M. M. 3
Aldigeri R. 1
Gardini S. 1
Ferrari-Pellegrini F. 1
Perini M. 1
Messa G. 4
Antonini M. 3
Spigoni V. 1
Cinquegrani G. 1
Vazzana A. 3
Moretti V. 3
Caffarra P. 5
Bonadonna R. C. 13
1 https://ror.org/02k7wn190 grid.10383.39 0000 0004 1758 0937 Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy
2 https://ror.org/01m39hd75 grid.488385.a 0000 0004 1768 6942 Division of Nutritional and Metabolic Sciences, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy
3 https://ror.org/01m39hd75 grid.488385.a 0000 0004 1768 6942 Division of Endocrinology and Metabolic Diseases, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy
4 Center for Cognitive Disorders, AUSL Parma, Via Verona 36, Parma, Italy
5 https://ror.org/02k7wn190 grid.10383.39 0000 0004 1758 0937 Department of Medicine and Surgery, Section of Neuroscience, University of Parma, Via Gramsci 14, 43126 Parma, Italy
2 4 2024
2 4 2024
2024
47 9 23392349
5 12 2023
23 1 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose

According to preclinical evidence, GLP-1 receptor may be an actionable target in neurodegenerative disorders, including Alzheimer’s disease (AD). Previous clinical trials of GLP-1 receptor agonists were conducted in patients with early AD, yielding mixed results. The aim was to assess in a proof-of-concept study whether slow-release exenatide, a long-acting GLP-1 agonist, can benefit the cognitive performance of people with mild cognitive impairment (MCI).

Methods

Thirty-two (16 females) patients were randomized to either slow-release exenatide (n = 17; 2 mg s.c. once a week) or no treatment (n = 15) for 32 weeks. The primary endpoint was the change in ADAS-Cog11 cognitive test score at 32 weeks vs baseline. Secondary endpoints herein reported included additional cognitive tests and plasma readouts of GLP-1 receptor engagement. Statistical analysis was conducted by intention to treat.

Results

No significant between-group effects of exenatide on ADAS-Cog11 score (p = 0.17) were detected. A gender interaction with treatment was observed (p = 0.04), due to worsening of the ADAS-Cog11 score in women randomized to exenatide (p = 0.018), after correction for age, scholar level, dysglycemia, and ADAS-Cog score baseline value. Fasting plasma glucose (p = 0.02) and body weight (p = 0.03) decreased in patients randomized to exenatide.

Conclusion

In patients with MCI, a 32-week trial with slow-release exenatide had no beneficial effect on cognitive performance.

Trial registration number

NCT03881371, registered on 21 July, 2016.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40618-024-02320-7.

Keywords

Exenatide
Mild cognitive impairment
GLP-1
ADAS-Cog
Diabetes Research Innovation (2015)DRINN project Dei Cas A. Università degli Studi di ParmaOpen access funding provided by Università degli Studi di Parma within the CRUI-CARE Agreement.

issue-copyright-statement© Italian Society of Endocrinology (SIE) 2024
==== Body
pmcIntroduction

Alzheimer’s disease (AD) represents the most common chronic neurodegenerative disorder, accounting for ~ 60–70% of all forms of dementia [1]. AD has a global overall prevalence of 3.9% in people ≥ 60 years [2] with over 43.8 million people suffering from AD, and this estimate is projected to double by 2050, mainly due to population aging [2]. Clinically, AD is characterized by a progressive memory loss paralleled by a subsequent decline in other cognitive domains, such as language and spatial orientation, aberrant behaviors, and impairments in activities of daily living, which ultimately make patients dependent on caregivers, representing a significant family, social and public health burden [2]. This overt clinical phase of AD is preceded by a variably long—up to several decades—preclinical phase, namely mild cognitive impairment (MCI), a cognitive stage between expected cognitive impairment of normal aging and the early stage of a more serious decline [3].

The two histologic pillars of AD diagnosis are amyloid beta protein (Ab) derived extracellular plaques and hyperphosphorylated tau derived intracellular neurofibrillary tangles [4]. However, there is a lack of consensus as to which of the two (or both? or neither?) play a pivotal role in the psycho-cognitive impairment of AD.

In the last 2 decades, AD has been also referred to as “Type 3 diabetes” to underline the strict link between metabolic alterations [5, 6] and the molecular, structural, biochemical, and functional abnormalities associated with neurodegeneration [7]. Specifically, defective insulin signaling i.e., insulin-resistance (IR) could be considered as a major pathogenetic intersection between type 2 diabetes (T2D) and AD [8]. Despite diabetes and AD can occur independently, the above definition pinpoints the existence of impaired shared pathways in the pathogenesis of both diseases, which confers to subjects with T2D a greater risk to develop AD and, possibly, vice versa [9, 10].

Glucagon-like Peptide 1 Receptor Agonists (GLP-1-RA) have shown promises to prevent or to treat neurodegenerative disorders, as part of extra-pancreatic actions; in preclinical studies, some of these compounds have been shown to cross the brain barrier and engage specific GLP-1 receptors, mainly located in the cerebral cortex, caudate putamen, hypothalamus including the ventromedial and arcuate nuclei, thalamus and globus pallidus [11]. The rationale and the potential role of GLP-1-RA in AD treatment have been thoroughly reviewed quite recently [12].

Importantly, several preclinical studies suggest that GLP-1 receptor engagement in the brain may—at least partially—restore a functional central downstream insulin signaling in AD [13]. However, despite robust preclinical evidence, clinical confirmation is yet to be determined.

While proof-of-concept studies have supported beneficial effects of exenatide [14–17] in patients with Parkinson’s disease, data with GLP-1-RA in AD/MCI are scant and not conclusive [18–20] and mainly limited to a few pilot studies in the overt clinical and irreversible AD phase.

We, therefore, conducted a pilot study aimed to assess the effects of the once-weekly administered long-acting GLP-1RA exenatide in preventing/slowing the progression of cognitive dysfunction in patients affected by MCI with or without dysglycemia. In addition, as secondary endpoints, we explored possible effects on metabolic parameters, hormone levels, and other neuropsychological tests of cognitive assessment.

Materials and methods

Study design

This is a 32-week, randomized (1:1), open-label, controlled proof-of-concept study comparing long-acting GLP-1 RA exenatide (2 mg once-weekly subcutaneous injection) versus no active intervention in patients affected by MCI with or without dysglycemia/prediabetes (NCT02847403). The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee “Comitato Etico per Parma” (Protocol number 34790, date of approval 16-sept-2015). Written informed consent was obtained from all subjects involved in the study.

Study population

Patients were recruited in the Centre for Cognitive Disorders and Dementia at Parma University Hospital (Italy). Inclusion criteria included age ≥ 50 and ≤ 80 years; Caucasian ethnicity, stable medications for the past 3 months and diagnosis of MCI according to the Petersen Clinical Criteria [21] (presence of subjective memory loss, preferably corroborated by an informant; demonstration of a memory impairment by cognitive testing; preserved general intellectual functioning as estimated by performance on a vocabulary test; intact ability to perform activities of daily living and absence of dementia) and Mini-Mental State Examination (MMSE) corrected scores from 24 to 27 [22]. Main exclusion criteria were: incapability to give informed consent; BMI ≤ 22 kg/m2; diagnosis of diabetes according to the American Diabetes Association (ADA) criteria [23]; significant neurologic disease other than MCI (i.e., Parkinson’s disease, multiple system atrophy, normal pressure hydrocephalus, progressive supra-nuclear palsy, subarachnoid hemorrhage, brain neoplasms, Huntington disease, epilepsy or head trauma); MRI/CT showing unambiguous etiological evidence of cerebrovascular disease with regard to MCI; clinically significant liver or kidney dysfunction defined as ALT > 2 times upper reference or estimated creatinine-clearance (eGFR) < 60 mL/min/1.73 m2, assessed by with CKD-EPI formula; endocrine diseases (other than well controlled hypothyroidism), personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia (MEN) syndrome; severe gastrointestinal diseases (i.e., gastroparesis, dumping syndromes), current or history of chronic or acute pancreatitis; current or history of cancer within the last 5 years; current clinically significant psychiatric disorder; any contraindication to the use of exenatide, warfarin treatment. All eligible women were post-menopausal.

Objectives

The main objective of the study was to compare the improvement of ADAS-cog Alzheimer’s Disease Assessment Scale at 16 and at 32 weeks with respect to baseline between the study groups.

Secondary goals included (1) absolute change in metabolic (fasting glycemia and HbA1C) and hormone levels and (2) improvements in neuropsychological evaluations at 16 and at 32 weeks compared to baseline between the two groups.

Study phases

Eligible patients underwent a baseline assessment and follow-up (FU) visits at 16 and 32 weeks after randomization. In addition, subjects on active treatment were admitted weekly to the outpatient Diabetes Unit for GLP-1RA subcutaneous injections (2 mg long-acting exenatide once-weekly) and side effect checking whereas those in the control arm were seen by the Centre for Cognitive Disorders and Dementia according to their usual schedule. At all three visits subjects underwent (1) anthropometric and hemodynamic assessment: weight and height for Body Mass Index (BMI) calculation, waist circumference, ambulatory systolic and diastolic blood pressure, heart rate; fasting blood sample and collection for metabolic/hormonal profile assessment: fasting plasma glucose, glycated hemoglobin A1c (HbA1c), insulin, peptide-C, glucagon, active GLP-1, total gastric inhibitory polypeptide (GIP), AST, ALT, pancreatic lipase, creatinine, and eGFR.; (2) a battery of neuropsychological tests for cognitive assessment administered by a trained neuropsychologist blinded to patient’s treatment: ADAS-Cog (11 items) (primary endpoint of this trial) [24], Mini-Mental State Examination (MMSE) [25], quality score of MMSE [26], Phonemic verbal fluency test [27], Semantic verbal fluency test [28], Geriatric Depression Scale (GDS) [29], Clinical Dementia Rating Scale (CDR) [30], Neuropsychiatric Inventory (NPI) [31], Activities of Daily Living (ADL) [32], and Instrumental Activities of Daily Living (IADL) [33].

A brain fMRI study for functional connectivity was performed at baseline and at 32 weeks for a companion study, to be reported separately.

Hormone profile assessment

Insulin, C-peptide, Glucagon, GIP, and total GLP-1 plasma concentrations were quantified in duplicate by ELISA assays (Mercodia AB, Uppsala, Sweden) and using standard curves, according to manufacturer’s instructions. Mean absorbance at 450 nm was read in a microplate reader (Multiskan™ FC Microplate Photometer, Thermo Scientific) to determine insulin, C-peptide, and glucagon concentrations. A luminescence plate reader (Victor, Perkin Elmer, Waltham, MA, USA) was used to calculate concentrations of GLP-1 and GIP.

The reported limits of detection were 1 mU/l, 25 pmol/l, 1 pmol/l, 1.62 pmol/l and 1 pmol/l for insulin, C-peptide, Glucagon, GIP, and total GLP-1, respectively.

Sample size

The sample size was determined based on the number of participants required to detect a clinically meaningful change in ADAS-cog of 0.71 (SD = 0.76). With a power of 80% at a 2-sided p < 0.05, one yields a minimal sample size of 18 per group. Assuming a drop-out rate ≤ 10%, the final estimate of the sample size is n = 20 per group.

Statistical methods

The analysis was based on the intention-to-treat (ITT) population. Categorical data were presented as numbers (percentages), and continuous data were presented as mean ± standard deviation (M ± SD) or median value and interquartile range (25–75%). Variables with non-normal distributions were logarithmically transformed before analysis. A GLM repeated-measures analysis was performed for the dependent (outcome) variables to determine whether the interventions produced the within-between group and interactive group × time effects, followed by post hoc tests of the variables. In the case of statistically significant interaction effects, paired t-tests for differences between baseline and after intervention within group and independent t-tests for differences between the two groups over time were conducted. A linear regression model for ADAS-Cog score was performed after adjusting for age, sex, scholar level, dysglycemia, and baseline ADAS-Cog score value. All tests were two-sided with a p ≤ 0.05 considered as statistically significant. All statistical analyses were performed using IBM SPSS Statistics version 27.0 software package (SPSS Inc., Chicago, IL, USA).

Results

Study population

Two hundred and seventy-six (n = 276) individuals affected by MCI with and without dysglycemia entered the screening phase and were assessed for eligibility. Figure 1 shows the CONSORT flow chart according to ITT analysis.Fig. 1 CONSORT flow chart

A total of 244 subjects (88%) were excluded because they did not meet the inclusion/exclusion criteria, while 20 eligible subjects (7%) declined to participate; 32 patients (n = 16 females and n = 16 males) were enrolled in the study between February 2016 and October 2018 (last patient follow-up at 32 weeks in July 2019). Subjects were randomized according to 1:1 ratio in open-label: 17 patients were assigned to receive exenatide and 15 patients were randomized to no active intervention. Six (2F, 4M) of the 17 subjects (35%) allocated to receive the active pharmacological intervention showed early treatment discontinuation, due to adverse gastrointestinal effects and mood swings. Of these, 2 patients interrupted the experimental drug at 3 weeks, 1 patient at 6, 1 patient at 8, 1 patient at 15 and the last subject at 20 weeks. All the subjects who discontinued experimental drug completed follow-up visits until the end of the study (32 week). In the control group, 1/15 (6.6%) subject discontinued from the study due to consent withdrawal. The mean time on treatment in the exenatide arm was 24 weeks (95% CI: 18–29 weeks). The median number of exenatide injections for patients in active treatment group was 31 (IQR: 15–32).

Baseline demographic and clinical characteristics of study population are reported in Table 1.Table 1 Demographic and clinical characteristics of study population at baseline. Data are presented as mean ± SD or n (%). BMI = body mass index

Variables	Total
(N = 32)	No treatment
(N = 15)	Exenatide (N = 17)	p-value	
Age (years)	73 ± 5	72 ± 6	74 ± 4	0.40	
Male sex n (%)	16(50)	8(53)	8(47)	0.87	
Smoking habit n (%)	3(9)	3(21)	0(0)	0.17	
Alcohol consumption n (%)	23(72)	10(64)	13(76)	0.46	
Weight (Kg)	73.0 ± 11.1	75.8 ± 11.4	70.5 ± 10.5	0.18	
BMI (Kg/m2)	27.2 ± 3.4	27.6 ± 3.3	27.0 ± 3.6	0.65	
BMI > 30 kg/m2	6(18.8)	4(27)	2(12)	0.28	
Waist circumference (cm)	97.0 ± 9.0	98.5 ± 11.5	96.1 ± 6.9	0.46	
Systolic blood pressure (mmHg)	132 ± 17	132 ± 14	133 ± 19	0.88	
Diastolic blood pressure (mmHg)	79 ± 11	80 ± 11	79 ± 11	0.76	
Heart rate (bpm)	69 ± 8	71 ± 7	67 ± 8	0.24	
Fasting plasma glucose (mg/dl)	92 ± 8	92 ± 11	92 ± 7	0.80	
HbA1c (mmol/mol)	36 ± 4	37 ± 3	35 ± 4	0.33	
Dysglycemia	11(34)	6(40)	5(29)	0.53	
AST (U/L)	26 ± 8	29 ± 10	24 ± 5	0.07	
ALT (U/L)	23 ± 13	25 ± 16	21 ± 10	0.68	
Lipase (U/L)	20 ± 13	19 ± 11	20 ± 15	0.74	
Creatinine (mg/dL)	0.81 ± 0.17	0.85 ± 0.16	0.77 ± 0.18	0.28	
eGFR (mL/min/1.73 m2)	82 ± 11	81 ± 12	83 ± 11	0.49	

The overall mean age at baseline was 73 ± 5 years, with gender equally represented in study groups. As expected with the randomization procedure, baseline features did not significantly differ between the study groups. Dysglycemia—defined as fasting plasma glucose (FPG) between 100 and 125 mg/dl and/or HbA1C levels between 39 and 46 mmol/mol—was present in 11 (34.3%) subjects with no differences between the study groups (29.4% in exenatide and 40% in the no treatment group p = 0.53).

Most frequent concomitant diseases associated with MCI at baseline were non-significant gastrointestinal diseases (50%), hypertension (47%), dyslipidemia (50%), genitourinary (31%) and mild neuropsychiatric disorders (31%). Concomitant medications at enrollment were mainly cardiovascular protective drugs (53%) and antihypertensive agents (31%), along with lipid lowering (50%), antithrombotic (31%) and anti-depressant/anxiety therapies (44%). Both concomitant diseases and medications resulted well balanced between the study groups at baseline.

Scholar level (p = 0.11) and neuropsychological test scores for cognitive assessment at baseline did not significantly differ between groups (data not shown). Specifically, ADAS-cog score was 14.05 ± 5.5 in the treated group vs 12.16 ± 5.44 in the no treated group (p = 0.34).

Exenatide effect on ADAS-Cog score (primary endpoint)

No significant time-dependent (p = 0.65) and treatment-dependent (p = 0.17) differences in ADAS-Cog scores were observed between the two study groups during the study (GLM repeated-measures, after adjustment for baseline score value) (Fig. 2A). These results were not affected by early discontinuation of the drug in 6/17 patients in the treatment group (p = 0.39).Fig. 2 ADAS-Cog test primary endpoint at baseline, 16 and 32 weeks of treatment in both study arms. Effect of treatment on ADAS-Cog score at baseline, 16 and 32 weeks, after correction for baseline value, in total population (n = 31) (A), males (n = 15) (B) and females (n = 16) (C). Estimated means ± SEM derived from GLM are shown. P-values for treatment effect are reported in the graph

In the GLM repeated measure model for ADAS-Cog score, after adjusting for age, gender, scholar level, presence of dysglycemia, and baseline ADAS-Cog score value, a significant interaction between female sex and treatment effect was identified (p = 0.04). In addition, a close to significant interaction between dysglycemia and female sex was shown (p = 0.06). By repeating the GLM analysis stratifying by sex, ADAS-Cog score resulted significantly increased in female patients, corresponding to cognitive performance worsening (p = 0.05), whereas the overall ADAS-Cog performance remained stable in male subjects throughout the study period (Fig. 2B, C). This result was confirmed also after adjustment for age, scholar level, and presence of dysglycemia (p = 0.018).

We then assessed possible treatment effects on each single of the 11 items composing ADAS-Cog. No differences were observed in any item between the two study groups (treated and untreated) (data not shown). Significant sex-related differences were recorded only for items number 8 (remembering test instructions) in the memory domain. Specifically, in relation to item 8 (remembering test instructions), the interaction between treatment and time resulted significant (p = 0.05) only in exenatide-treated females, who showed a worse cognitive performance (corresponding to an increased score) compared to untreated patients, after correction for baseline values (Fig. 3A, B).Fig. 3 Sex-stratified remembering test instructions test at baseline, 16 and 32 weeks of treatment in both study arms. Effect of treatment on remembering test instruction at baseline, 16 and 32 weeks, after correction for baseline values, in males (n = 15) (A) and females (n = 16) (B). Estimated means ± SEM derived from GLM are shown. P-values for treatment*time interaction effect are reported in the graph

Exenatide effects on clinical, metabolic and incretin peptide levels

A significant decrease in fasting plasma glucose was present in the exenatide-treated subjects during the study (p = 0.02), without sex differences (GLM repeated-measures), whereas no difference was recorded for HbA1c (p = 0.93). As expected, weight reduction was observed in the exenatide arm during the study compared to untreated subjects (p = 0.03) without sex differences. No significant time and treatment effects were recorded for waist circumference, systolic and diastolic blood pressure, and heart rate [34].

Similarly, insulin, C-peptide, glucagon, active GLP-1, total gastric inhibitory polypeptide (GIP) assays showed no differences between study groups during follow-up [39].

Exenatide effects on neuropsychological tests for cognitive assessment (secondary endpoints)

No significant changes in MMSE, CDR, GDS and NPI and phonemic fluency scores were observed between study groups (GLM repeated-measures) during follow-up. Conversely, a treatment (p = 0.04) and time-dependent (p = 0.02) effect of exenatide in IADL score reduction, corresponding to a mild worsening of subject autonomy in instrumental activities of daily life and a significant treatment*time effect (p = 0.03) reduction in semantic fluency scores were observed (Table 2).Table 2 Neuropsychological test scores for cognitive assessment relative to both study groups at baseline, 16 and 32 weeks. Data are presented as mean ± SD and p-values derived from GLM repeated-measures

Variables	No treatment
(N = 14)	Exenatide
(N = 17)	GLM p-values	
Time	Treatment	Time*treatment	
MMSE			0.64	0.10	0.12	
 Baseline	26.1 ± 1.8	25.9 ± 1.3	
 16 weeks	27.1 ± 2.4	25.8 ± 3.8	
 32 weeks	27.2 ± 2.1	24.6 ± 5.0	
CDR			0.28	0.51	0.65	
 Baseline	0.30 ± 0.32	0.26 ± 0.26	
 16 weeks	0.18 ± 0.25	0.27 ± 0.26	
 32 weeks	0.29 ± 0.26	0.35 ± 0.34	
GDS			0.54	0.4	0.54	
 Baseline	2.5 ± 2.8	2.2 ± 2.0	
 16 weeks	3.1 ± 2.7	2.2 ± 2.5	
 32 weeks	2.4 ± 2.1	1.9 ± 1.7	
NPI			0.62	0.42	0.31	
 Baseline	10.4 ± 11.3	5.8 ± 4.1	
 16 weeks	8.7 ± 8.0	6.8 ± 5.7	
 32 weeks	7.9 ± 5.5	7.5 ± 5.7	
IADL			0.02*	0.04*	0.08	
 Baseline	1.00 ± 0	0.99 ± 0.05	
 16 weeks	0.99 ± 0.03	0.94 ± 0.11	
 32 weeks	0.99 ± 0.04	0.89 ± 0.16	
Phonemic fluency			0.97	0.25	0.18	
 Baseline	30.3 ± 11.1	29.0 ± 13.0	
 16 weeks	31.6 ± 10.9	27.2 ± 13.7	
 32 weeks	33.9 ± 11.1	27.1 ± 12.6	
Semantic fluency			0.30	0.04*	0.03*	
 Baseline	30.0 ± 8.0	26.0 ± 9.7	
 16 weeks	31.9 ± 6.4	25.2 ± 10.5	
 32 weeks	31.9 ± 6.8	23.6 ± 10.6	

These effects were confirmed to be more evident in females: a time-dependent decrease in IADL scores (p = 0.03), and a time and treatment effect in semantic fluency score reduction were observed (p = 0.03) in the female sex at 32 weeks (data not shown).

Treatment safety and adverse events

Exenatide resulted to be safe, as no significant treatment-dependent changes in lipase, liver enzymes and creatinine values were observed from baseline to the end of follow-up. A significant amelioration of creatinine was observed in the exenatide arm compared to untreated subjects (p = 0.01) [39].

No significant difference in the overall adverse events (AEs) occurrence was described between the study arms (p = 0.12) (Table 3). A total number of 18 adverse events, 12 AEs (70.6%) in the exenatide group and 6 (43%) AEs in the control group, respectively, were recorded during the study period, without any serious adverse event. An overall of 18/31 (58.1%) subjects experienced at least one AE during the follow-up period, without significant differences among sex (8/16 F, 10/15 M, p = 0.35). As expected, exenatide-treated subjects showed a significant higher incidence of gastrointestinal adverse events, in particular nausea and decreased appetite, compared to untreated subjects (p < 0.01) which in 6 subjects led to drug discontinuation.Table 3 Adverse event rates recorded in both study groups during the follow-up period. Data are presented as n (%)

Adverse events	All patients (N = 31)	No treatment (N = 14)	Exenatide (N = 17) (N = 17)	p-value	
Gastrointestinal	9 (29.0)	0 (0)	9 (52.9)	 < 0.001	
Neuropsychiatric	3 (9.7)	0 (0)	3 (17.6)	0.1	
Other	9(29.0)	6 (42.8)	3 (17.6)	0.12	
At least one AE	18 (58.1)	6 (42.8)	12 (70.6)	0.12	

Discussion

In this proof-of-concept study, we tested the hypothesis that the treatment with the long-acting GLP-1 RA exenatide could prevent or slow down the progression of cognitive decline in MCI subjects, measured with the ADAS-Cog score, when compared to no active intervention. In parallel, we assessed commensurate changes of other relevant neuropsychological tests for cognitive assessment and of clinical and metabolic parameters.

At present, AD is symptomatically treated with pharmacological agents which mainly act on the neurotransmission impairment rather than targeting the underlying pathogenetic mechanisms. More importantly, no behavioral/nutritional/pharmacological interventions have been shown to be effective in preventing or slowing the progression of cognitive impairment in the continuum from MCI to overt AD.

A robust body of evidence shows that AD might be sustained by the impairment of insulin signaling in the brain and, therefore, that IR, which is a pathogenetic key aspect of T2D, could be considered a specific target for AD treatment. Based on this working hypothesis, incretin-based therapies have been repurposed as major candidates to prevent or treat neurodegenerative disorders, as they have been shown to restore insulin signaling in the brain by engaging neural GLP-1 receptor [35]. However, despite biological plausibility and strong preclinical evidence, scant and contrasting literature is available about the disease-modifying properties of GLP-1-RAs in humans affected by MCI or AD.

Glucose metabolism is altered in AD, with reductions in glucose bioavailability, owing to impaired permeability of the blood–brain barrier, and in glucose metabolism, leading to defects in glucose transport/phosphorylation. In healthy humans, the administration of GLP-1 results into 25–30% fall in glucose metabolism of gray matter across various brain regions [36]. In previous pilot studies with GLP-1-RAs, 4 weeks of liraglutide intervention prevented the decline of glucose metabolism ([18F]FDG (FDG) in subjects with AD, although the study was unpowered to draw conclusions on the Aβ load or on cognition measures, which were unchanged [23]. In a different study, 6 months of liraglutide treatment in patients with AD improved glucose transfer across the blood–brain barrier, thereby enhancing glucose bioavailability [24]. More recently, 12-week treatment with liraglutide significantly increased brain connectivity assessed by fMRI compared to placebo in subjects at risk for AD (half of subjects with a family history of AD), with no detectable cognitive differences between study groups at the end of the study [25]; exenatide treatment produced no differences or trends compared to placebo for clinical and cognitive measures, MRI cortical thickness and volume, or biomarkers in cerebrospinal fluid, plasma, and plasma neuronal extracellular vesicles (EV) except for a reduction in amyloid β isoform Aβ42 in EVs [37].

These human studies yielded mixed findings and were limited by small sample size, short duration and relevant heterogeneity in study populations and primary endpoints. Pooled data from three randomized double‐blind placebo‐controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry‐based cohort (120,054 patients) showed lower dementia rate in patients randomized to GLP‐1 RAs versus placebo [38]. In line, in the Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) study a pre-determined post hoc analysis showed that in patients with type 2 diabetes mellitus a 5-year treatment with dulaglutide could slow down the cognitive decline [39]. In addition, REWIND is fraught with the important limitation that both the decline and the dulaglutide attributable protection of cognitive function remain undetermined with regard to their etiologies.

No human data are available to date on the effect of semaglutide on cognitive function, ongoing trials will give insight on this issue (NCT04777409, NCT04777396).

Hoping to improve the power of our study, AD was targeted in its preclinical stage—MCI—, in which the slope of the decline in cognitive function and of the changes in disease biomarkers may be steepest. Furthermore, MCI also is a desirable stage for intervention [40] in which stopping, or even simply delaying, the deterioration of cognitive function would leave the patient with a good deal of autonomy. In addition, we planned a somewhat longer follow-up compared to some previous studies. Long-acting exenatide also has the advantage of once-weekly administration, which facilitates patient compliance and may show better tolerability than short acting GLP-1 RAs.

The results of our study show that exenatide was unable to prompt any detectable improvement in the disease evolution. Human data demonstrated that cerebrospinal fluid levels of exenatide are 2% of plasma levels in subjects with Parkinson disease following long-acting exenatide administration [41] and higher systemic doses might be necessary to be clinically relevant on the CNS.

An interesting finding in our study is the significant interaction between female sex and treatment effect. In our study, women treated with exenatide showed an acceleration of cognitive impairment. Although this may be entirely due to the play of chance, some evidence suggests that GLP-1-RA perhaps may exert sex-related effects. This should be viewed in the context of AD, which displays several sex-related features, including sex differences in the genetic architecture [42].

Women display an almost twofold increased risk of developing [43] and female sex has been recognized as a predictor of disease progression [44].

If the longer life span in women increases by itself the lifelong risk of AD, it cannot explain sex-related differences in incidence at ages of 60–80 in age-matched cohorts. These data are consistent with possible effects of estrogens on brain structure and functions, including learning and memory [45, 46]. Data supporting the relationship between estrogen depletion in aging and the risk of AD in females have been provided mainly by experimental studies in animals, while evidence is less consistent in humans as whether estrogen-based hormone therapy attenuates AD risk in post-menopausal women [47, 48]. Of note, all women enrolled were post-menopausal and without hormone therapy.

Suggestions of the existence of a sex-related response to GLP-1 RAs action on another parameter—weight—are provided by a retrospective analysis with liraglutide [49]. A recent review on sex dimorphism in the pharmacology of anti-obesity drugs suggests that many pharmacodynamics and pharmacokinetics factors may be responsible for sex-related disparities in the efficacy of these compounds [50].

Among the secondary endpoints, the average scores of the individual neuropsychological tests, used for cognitive assessment, did not significantly change in the study groups from baseline to the end of the study, with the exception of lexical retrieval and production and instrumental activities of daily living, which were reduced in exenatide-treated subjects: these results were probably again driven by the female sex which showed a worse cognitive performance in these domains.

We report, as expected, a decrease in fasting plasma glucose and body weight in the subjects treated with exenatide, with no sex differences, suggesting that exenatide effects on cognitive function are only loosely connected, or not connected at all, to its metabolic effects.

Exenatide resulted to be safe, but with the expected spectrum of side effects. The group on active treatment reported gastrointestinal discomfort and symptoms, mostly mild and transient nausea and mild to moderate loss of appetite. However, six subjects enrolled in the exenatide group early discontinued treatment because of gastrointestinal side effects, and this proportion is numerically higher than it has been reported in large trials in patients with type 2 diabetes. On the other hand, no serious adverse events were observed.

The clinical relevance and innovation of this study was to target AD in its preclinical stage (i.e., MCI), that is before irreversible invalidating clinical AD symptoms occur, in which, however, the likelihood and rapidity of conversion to AD is greatest. In this context, GLP-1 RA has been proposed in condition of non-diabetes hyperglycemia to rule out possible confounders,—mainly cardiovascular burden and concomitant anti diabetes therapies—, which may have pointed to a novel clinical application of GLP-1 RA in MCI, targeting outcomes other than glucose control. Some important limitations in the present study should be mentioned. Six patients on active treatment (35%) early discontinued exenatide due to gastrointestinal adverse effects, however, this did not significantly influence changes in ADAS-Cog scores between the two study arms. The small sample size, the high number of dropouts, some counterintuitive results and the short duration of the study importantly precluded definite clinical conclusions.

This proof-of-concept study does not support the efficacy of incretin-based therapies to modify the natural history of AD, even at the early stage of MCI. Although the study results do not lead to definite clinical conclusions, they encourage further clinical investigations on GLP-1R as a potentially actionable target in MCI/AD and on sex-related differences in the treatment responses to GLP-1 RA.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 18 KB)

Supplementary file2 (DOCX 16 KB)

Supplementary file3 (DOCX 15 KB)

Acknowledgements

Not applicable.

Author contributions

Conceptualization, ADC and RCB; methodology, PC and SG; formal Analysis, RA; investigation, MMM, GM, MA, MP, FFP, AV, VM; data curation, RA, VS and GC; writing—original draft preparation, ADC; writing—review and editing, ADC, MMM, RA, RCB, PC, MA, AV, VM, PC, FFP, MP, SG, GC, VS; supervision, RCB; project administration, ADC; funding acquisition, ADC.

Funding

Open access funding provided by Università degli Studi di Parma within the CRUI-CARE Agreement. This work was supported by DRINN Project—Diabetes Research Innovation (2015).

Availability of data and materials

Data that support the findings of this study are available from the corresponding author, [ADC], upon reasonable request.

Declarations

Conflict of interest

The authors declare no conflict of interest.

Ethics approval and consent to participate

The study was approved by the Ethics Committee “Comitato Etico per Parma” (Protocol number 34790, date of approval 16-sept-2015). Written informed consent was obtained from all subjects involved in the study.

Informed consent

Written informed consent to publish was obtained from all subjects involved in the study.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

A. D. Cas and M. M. Micheli contributed equally to this work.
==== Refs
References

1. www.who.int/news-room/fact-sheets/detail/dementia. Accessed 20 Sep 2022.
2. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18, 88–106.
3. Dubois B Villain N Frisoni GB Rabinovici GD Sabbagh M Cappa S Bejanin A Bombois S Epelbaum S Teichmann M Habert MO Nordberg A Blennow K Galasko D Stern Y Rowe CC Salloway S Schneider LS Cummings JL Feldman HH Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group Lancet Neurol 2021 20 484 496 10.1016/S1474-4422(21)00066-1 33933186
Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH (2021) Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol 20:484–49633933186 10.1016/S1474-4422(21)00066-1
4. Norwitz NG Mota AS Norwitz SG Clarke K Multi-loop model of Alzheimer disease: an integrated perspective on the Wnt/GSK3β, α-synuclein, and type 3 diabetes hypotheses Front Aging Neurosci 2019 11 184 10.3389/fnagi.2019.00184 31417394
Norwitz NG, Mota AS, Norwitz SG, Clarke K (2019) Multi-loop model of Alzheimer disease: an integrated perspective on the Wnt/GSK3β, α-synuclein, and type 3 diabetes hypotheses. Front Aging Neurosci 11:18431417394 10.3389/fnagi.2019.00184
5. De la Monte SM Tong M Brain metabolic dysfunction at the core of Alzheimer's disease Biochem Pharmacol 2014 88 548 559 10.1016/j.bcp.2013.12.012 24380887
De la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 88:548–55924380887 10.1016/j.bcp.2013.12.012
6. De la Monte SM Type 3 diabetes is sporadic Alzheimers disease: mini-review Eur Neuropsychopharmacol 2014 24 1954 1960 10.1016/j.euroneuro.2014.06.008 25088942
De la Monte SM (2014) Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol 24:1954–196025088942 10.1016/j.euroneuro.2014.06.008
7. Steen E Terry BM Rivera EJ Cannon JL Neely TR Tavares R Xu XJ Wands JR de la Monteet SM Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease -is this type 3 diabetes? J Alzheimers Dis 2005 7 63 80 10.3233/JAD-2005-7107 15750215
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monteet SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease -is this type 3 diabetes? J Alzheimers Dis 7:63–8015750215 10.3233/JAD-2005-7107
8. Bosco D Fava A Plastino M Montalcini T Pujia A Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis J Cell Mol Med 2011 15 1807 1821 10.1111/j.1582-4934.2011.01318.x 21435176
Bosco D, Fava A, Plastino M, Montalcini T, Pujia A (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. J Cell Mol Med 15:1807–182121435176 10.1111/j.1582-4934.2011.01318.x
9. Ott A Stolk RP van Harskamp F Pols HA Hofman A Breteler MM Diabetes mellitus and the risk of dementia: the Rotterdam study Neurology 1999 53 1937 1942 10.1212/WNL.53.9.1937 10599761
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53:1937–194210599761 10.1212/WNL.53.9.1937
10. Crane PK Walker R Hubbard RA Li G Nathan DM Zheng H Haneuse S Craft S Montine TJ Kahn SE McCormick W McCurry SM Bowen JD Larson EB Glucose levels and risk of dementia N Engl J Med 2013 369 540 548 10.1056/NEJMoa1215740 23924004
Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE, McCormick W, McCurry SM, Bowen JD, Larson EB (2013) Glucose levels and risk of dementia. N Engl J Med 369:540–54823924004 10.1056/NEJMoa1215740
11. Alvarez E Martínez MD Roncero I Chowen JA García-Cuartero B Gispert JD Sanz C Vázquez P Maldonado A De Cáceres J Desco M Pozo MA Blázquez E The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem J Neurochem 2005 92 798 806 10.1111/j.1471-4159.2004.02914.x 15686481
Alvarez E, Martínez MD, Roncero I, Chowen JA, García-Cuartero B, Gispert JD, Sanz C, Vázquez P, Maldonado A, De Cáceres J, Desco M, Pozo MA, Blázquez E (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92:798–80615686481 10.1111/j.1471-4159.2004.02914.x
12. Reich N Hölscher C The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review Front Neurosci 2022 16 970925 10.3389/fnins.2022.970925 36117625
Reich N, Hölscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci 16:97092536117625 10.3389/fnins.2022.970925
13. Zhou M Chen S Peng P Gu Z Yu J Zhao G Deng Y Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β Biochem Biophys Res Commun 2019 511 154 160 10.1016/j.bbrc.2019.01.103 30773255
Zhou M, Chen S, Peng P, Gu Z, Yu J, Zhao G, Deng Y (2019) Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β. Biochem Biophys Res Commun 511:154–16030773255 10.1016/j.bbrc.2019.01.103
14. Viles-Olmos IA Dickson J Kefalopoulou Z Djamshidian A Ell P Soderlund T Whitton P Wyse R Isaacs T Lees A Limousin P Foltynie T Exenatide and the treatment of patients with Parkinson’s disease J Clin Invest 2013 123 2730 2736 10.1172/JCI68295 23728174
Viles-Olmos IA, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2013) Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 123:2730–273623728174 10.1172/JCI68295
15. Aviles-Olmos I Dickson J Kefalopoulou Z Djamshidian A Kahan J Ell P Whitton P Wyse R Isaacs T Lees A Limousin P Foltynie T Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease J Parkinsons Dis 2014 4 3 337 344 10.3233/JPD-140364 24662192
Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis 4(3):337–34424662192 10.3233/JPD-140364
16. Athauda D Maclagan K Skene SS Bajwa-Joseph M Letchford D Chowdhury K Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial Lancet 2017 390 1664 1675 10.1016/S0140-6736(17)31585-4 28781108
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–167528781108 10.1016/S0140-6736(17)31585-4
17. Athauda D Gulyani S Karnati HK Li Y Tweedie D Mustapic M Chawla S Chowdhury K Skene SS Greig NH Kapogiannis D Foltynie T Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the exenatide-PD trial JAMA Neurol 2019 76 4 420 429 10.1001/jamaneurol.2018.4304 30640362
Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T (2019) Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol 76(4):420–42930640362 10.1001/jamaneurol.2018.4304
18. Gejl M Gjedde A Egefjord L Møller A Hansen SB Vang K Rodell A Brændgaard H Gottrup H Schacht A Møller N Brock B Rungby J In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial Front Aging Neurosci 2016 8 108 10.3389/fnagi.2016.00108 27252647
Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, Rodell A, Brændgaard H, Gottrup H, Schacht A, Møller N, Brock B, Rungby J (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 8:10827252647 10.3389/fnagi.2016.00108
19. Gejl M Brock B Egefjord L Vang K Rungby J Gjedde A Blood-brain glucose transfer in Alzheimer's disease: effect of GLP-1 analog treatment Sci Rep 2017 7 17490 10.1038/s41598-017-17718-y 29235507
Gejl M, Brock B, Egefjord L, Vang K, Rungby J, Gjedde A (2017) Blood-brain glucose transfer in Alzheimer’s disease: effect of GLP-1 analog treatment. Sci Rep 7:1749029235507 10.1038/s41598-017-17718-y
20. Watson KT Wroolie TE Tong G Foland-Ross LC Frangou S Singh M McIntyre RS Roat-Shumway S Myoraku A Reiss AL Rasgon NL Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease Behav Brain Res 2019 356 271 278 10.1016/j.bbr.2018.08.006 30099030
Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL (2019) Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease. Behav Brain Res 356:271–27830099030 10.1016/j.bbr.2018.08.006
21. Petersen RC Mild cognitive impairment as a diagnostic entity J Int Med 2004 256 183 194 10.1111/j.1365-2796.2004.01388.x
Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Int Med 256:183–19410.1111/j.1365-2796.2004.01388.x
22. Measso G Cavarzeran F Zappalà G Lebowitz BD Crook TH Pirozzolo FJ Amaducci LA Massari D Grigoletto F The mini-mental state examination: Normative study of an Italian random sample Dev Neuropsychol 1993 9 77 85 10.1080/87565649109540545
Measso G, Cavarzeran F, Zappalà G, Lebowitz BD, Crook TH, Pirozzolo FJ, Amaducci LA, Massari D, Grigoletto F (1993) The mini-mental state examination: Normative study of an Italian random sample. Dev Neuropsychol 9:77–8510.1080/87565649109540545
23. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 2013 36 Suppl. 1 S67 S74 10.2337/dc13-S067 23264425
American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl. 1):S67–S7423264425 10.2337/dc13-S067
24. Rosen WG A new rating scale for Alzheimer’s disease Am J Psychiatry 1984 141 11 1356 1364 10.1176/ajp.141.11.1356 6496779
Rosen WG (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141(11):1356–13646496779 10.1176/ajp.141.11.1356
25. Magni E Binetti G Padovani A Cappa SF Bianchetti A Trabucchi M The Mini-Mental State Examination in Alzheimer's disease and multi-infarct dementia Int Psychogeriatr 1996 8 1 127 134 10.1017/S1041610296002529 8805093
Magni E, Binetti G, Padovani A, Cappa SF, Bianchetti A, Trabucchi M (1996) The Mini-Mental State Examination in Alzheimer’s disease and multi-infarct dementia. Int Psychogeriatr 8(1):127–1348805093 10.1017/S1041610296002529
26. Caffarra P Gardini S Dieci F Copelli S Maset L Concari L Farina E Grossi E The qualitative scoring MMSE pentagon test (QSPT): a new method for differentiating dementia with Lewy Body from Alzheimer's disease Behav Neurol 2013 27 2 213 220 10.1155/2013/728158 23396218
Caffarra P, Gardini S, Dieci F, Copelli S, Maset L, Concari L, Farina E, Grossi E (2013) The qualitative scoring MMSE pentagon test (QSPT): a new method for differentiating dementia with Lewy Body from Alzheimer’s disease. Behav Neurol 27(2):213–22023396218 10.1155/2013/728158
27. Carlesimo GA Caltagirone C Gainotti G The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery Eur Neurol 1996 36 6 378 384 10.1159/000117297 8954307
Carlesimo GA, Caltagirone C, Gainotti G (1996) The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur Neurol 36(6):378–3848954307 10.1159/000117297
28. Novelli G Papagno C Capitani E Three clinical tests for the assessment of lexical retrieval and production. Norms from 320 normal subjects Arch Psicol Neurol Psichiatr 1986 47 4 477 506
Novelli G, Papagno C, Capitani E et al (1986) Three clinical tests for the assessment of lexical retrieval and production. Norms from 320 normal subjects. Arch Psicol Neurol Psichiatr 47(4):477–506
29. Yesavage JA Brink TL Rose TL Lum O Huang V Adey M Leirer VO Development and validation of a geriatric depression screening scale: a preliminary report J Psych Res 1983 17 37 49 10.1016/0022-3956(82)90033-4
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psych Res 17:37–4910.1016/0022-3956(82)90033-4
30. Hughes CP Berg L Danziger WL Coben LA Martin RL A new clinical scale for the staging of dementia Br J Psychiatry 1982 140 566 572 10.1192/bjp.140.6.566 7104545
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–5727104545 10.1192/bjp.140.6.566
31. Cummings JL Mega M Gray K Rosenberg-Thompson S Carusi DA Gornbein J The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia Neurology 1994 44 2308 2314 10.1212/WNL.44.12.2308 7991117
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–23147991117 10.1212/WNL.44.12.2308
32. Derouesné C Thibault S Lozeron P Baudouin-Madec V Piquard A Lacomblez L Perturbations of activities of daily living in Alzheimer's disease. A study of 172 patients with the using a questionnaire completed by caregivers Rev Neurol (Paris). 2002 158 684 700 12486898
Derouesné C, Thibault S, Lozeron P, Baudouin-Madec V, Piquard A, Lacomblez L (2002) Perturbations of activities of daily living in Alzheimer’s disease. A study of 172 patients with the using a questionnaire completed by caregivers. Rev Neurol (Paris). 158:684–70012486898
33. Lawton MP Brody EM Assessment of older people: self-maintaining and instrumental activities of daily living Gerontologist 1969 9 3 179 186 10.1093/geront/9.3_Part_1.179 5349366
Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9(3):179–1865349366 10.1093/geront/9.3_Part_1.179
34. 10.5281/zenodo.10069131
35. Yaribeygi H Rashidy-Pour A Atkin SL Jamialahmadi T Sahebkar A GLP-1 mimetics and cognition Life Sci 2021 264 118645 10.1016/j.lfs.2020.118645 33121988
Yaribeygi H, Rashidy-Pour A, Atkin SL, Jamialahmadi T, Sahebkar A (2021) GLP-1 mimetics and cognition. Life Sci 264:11864533121988 10.1016/j.lfs.2020.118645
36. Lerche S Brock B Rungby J Bøtker HE Møller N Rodell A Bibby BM Holst JJ Schmitz O Gjedde A Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans Diabetes 2008 57 325 331 10.2337/db07-1162 17991759
Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, Bibby BM, Holst JJ, Schmitz O, Gjedde A (2008) Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes 57:325–33117991759 10.2337/db07-1162
37. Mullins RJ Mustapic M Chia CW Carlson O Gulyani S Tran J Li Y Mattson MP Resnick S Egan JM Greig NH Kapogiannis D A Pilot Study of Exenatide Actions in Alzheimer's Disease Curr Alzheimer Res 2019 16 741 752 10.2174/1567205016666190913155950 31518224
Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D (2019) A Pilot Study of Exenatide Actions in Alzheimer’s Disease. Curr Alzheimer Res 16:741–75231518224 10.2174/1567205016666190913155950
38. Nørgaard CH Friedrich S Hansen CT Gerds T Ballard C Møller DV Knudsen LB Kvist K Zinman B Holm E Torp-Pedersen C Mørch LS Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers Alzheimers Dement (N Y) 2022 8 1 e12268 10.1002/trc2.12268 35229024
Nørgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Møller DV, Knudsen LB, Kvist K, Zinman B, Holm E, Torp-Pedersen C, Mørch LS (2022) Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y) 8(1):e1226835229024 10.1002/trc2.12268
39. Cukierman-Yaffe T Gerstein HC Colhoun HM Diaz R García-Pérez LE Lakshmanan M Bethel A Xavier D Probstfield J Riddle MC Rydén L Atisso CM Hall S Rao-Melacini P Basile J Cushman WC Franek E Keltai M Lanas F Leiter LA Lopez-Jaramillo P Pirags V Pogosova N Raubenheimer PJ Shaw JE Sheu WH Temelkova-Kurktschiev T Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial Lancet Neurol 2020 19 7 582 590 10.1016/S1474-4422(20)30173-3 32562683
Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, García-Pérez LE, Lakshmanan M, Bethel A, Xavier D, Probstfield J, Riddle MC, Rydén L, Atisso CM, Hall S, Rao-Melacini P, Basile J, Cushman WC, Franek E, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 19(7):582–59032562683 10.1016/S1474-4422(20)30173-3
40. Lewczuk P Mroczko B Fagan A Kornhuber J Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective Adv Med Sci 2014 60 76 82 10.1016/j.advms.2014.11.002 25579841
Lewczuk P, Mroczko B, Fagan A, Kornhuber J (2014) Biomarkers of Alzheimer’s disease and mild cognitive impairment: a current perspective. Adv Med Sci 60:76–8225579841 10.1016/j.advms.2014.11.002
41. Athauda D Maclagan K Skene SS Bajwa-Joseph M Letchford D Chowdhury K Hibbert S Budnik N Zampedri L Dickson J Li Y Aviles-Olmos I Warner TT Limousin P Lees AJ Greig NH Tebbs S Foltynie T Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial Lancet 2017 390 10103 1664 1675 10.1016/S0140-6736(17)31585-4 28781108
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664–167528781108 10.1016/S0140-6736(17)31585-4
42. Dumitrescu L Mayeda ER Sharman K Moore AM Hohman TJ Sex Differences in the genetic architecture of Alzheimer's disease Curr Genet Med Rep 2019 7 13 21 10.1007/s40142-019-0157-1 31360619
Dumitrescu L, Mayeda ER, Sharman K, Moore AM, Hohman TJ (2019) Sex Differences in the genetic architecture of Alzheimer’s disease. Curr Genet Med Rep 7:13–2131360619 10.1007/s40142-019-0157-1
43. Seshadri S Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham Study Neurology 1997 49 1498 1504 10.1212/WNL.49.6.1498 9409336
Seshadri S et al (1997) Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 49:1498–15049409336 10.1212/WNL.49.6.1498
44. Li J-Q Tan L Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies J Neurol Neurosurg Psychiatry 2016 87 476 484 10.1136/jnnp-2014-310095 26001840
Li J-Q, Tan L et al (2016) Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry 87:476–48426001840 10.1136/jnnp-2014-310095
45. Cahill L Why sex matters for neuroscience Nat Rev Neurosci 2006 7 477 484 10.1038/nrn1909 16688123
Cahill L (2006) Why sex matters for neuroscience. Nat Rev Neurosci 7:477–48416688123 10.1038/nrn1909
46. Andreano JM Cahill L Sex influences on the neurobiology of learning and memory Learn Mem 2009 16 248 266 10.1101/lm.918309 19318467
Andreano JM, Cahill L (2009) Sex influences on the neurobiology of learning and memory. Learn Mem 16:248–26619318467 10.1101/lm.918309
47. Shumaker SA Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study JAMA 2004 291 2947 2958 10.1001/jama.291.24.2947 15213206
Shumaker SA et al (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 291:2947–295815213206 10.1001/jama.291.24.2947
48. Maki PM Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies Manopause 2013 20 695 709 10.1097/GME.0b013e3182960cf8
Maki PM (2013) Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Manopause 20:695–70910.1097/GME.0b013e3182960cf8
49. Wilding JP Overgaard RV Jacobsen LV Jensen CB Le Roux CW Exposure-response analyses of liraglutide 3.0 mg for weight management Diabetes Obes Metab 2016 18 491 499 10.1111/dom.12639 26833744
Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, Le Roux CW (2016) Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab 18:491–49926833744 10.1111/dom.12639
50. Cataldi M Muscogiuri G Savastano S Barrea L Guida B Taglialatela M Colao A Gender-related issues in the pharmacology of new anti-obesity drugs Obes Rev 2019 20 375 384 10.1111/obr.12805 30589980
Cataldi M, Muscogiuri G, Savastano S, Barrea L, Guida B, Taglialatela M, Colao A (2019) Gender-related issues in the pharmacology of new anti-obesity drugs. Obes Rev 20:375–38430589980 10.1111/obr.12805
